TY - JOUR
T1 - Prevalence of anal human papillomavirus vaccine types in the Bangkok men who have sex with men cohort study
AU - Cranston, Ross D.
AU - Althouse, Andrew D.
AU - Van Griensven, Frits
AU - Janocko, Laura
AU - Curlin, Marcel E.
AU - Chaikummao, Supaporn
AU - Chonwattana, Wannee
AU - Siegel, Aaron
AU - Holtz, Timothy H.
AU - McGowan, Ian
N1 - Publisher Copyright:
© 2015 American Sexually Transmitted Diseases Association. All rights reserved.
PY - 2015
Y1 - 2015
N2 - Background: The quadrivalent human papillomavirus (qHPV) and 9 valent (nHPV) vaccine are licensed for males to prevent anal HPV-associated dysplasia and cancer caused by HPV types 6, 11, 16, and 18 (qHPV) and additional types 33, 35, 45, 52, and 58 (nHPV), respectively. Both conditions are common in HIV-infected and HIV-uninfected men who have sex with men (MSM). It is not well documented which anal HPV vaccine types are most prevalent in Southeast Asia. Methods: A convenience sample of 400 anal swabs were obtained from 200 HIV-infected and 200 HIV-uninfected sexually active Bangkok MSM Cohort Study participants. After swab collection in PreservCyt (Cytyc Corp,Marlborough,MA), the media was stored at.80°C until processing. DNA was extracted, amplified by polymerase chain reaction, denatured, and then hybridized to probes for 37 HPV types and â-globin. Results: The mean participant age was 25.6 years (range, 18-55 years); the mean CD4 T-cell count was 410 cells/mm3 in the HIV-infected participants. Among all swab samples, 386 (192 HIV-positive and 194 HIVnegative) had adequate â-globin for HPV genotype testing. Anal HPV type was detected in 44.3% of participants whose samples underwent genotype testing. Both qHPVand nHPV types were more frequently detected in HIVinfected compared with HIV-uninfected (42.2% vs. 23.2% [P < 0.01], 50.0% vs. 24.2% [P < 0.01]), respectively). There were no significant relationships between social behaviors (alcohol use, drug use) or sexual behaviors (number of partners, condom usage, sexual positioning) and anal HPV prevalence. Conclusions: The prevalence of anal vaccine HPV types in Thai MSM was similar to that reported in MSM from Western populations and has a similar distribution by HIV status. Targeting youngMSMwith vaccination could offer protection against HPV vaccine types.
AB - Background: The quadrivalent human papillomavirus (qHPV) and 9 valent (nHPV) vaccine are licensed for males to prevent anal HPV-associated dysplasia and cancer caused by HPV types 6, 11, 16, and 18 (qHPV) and additional types 33, 35, 45, 52, and 58 (nHPV), respectively. Both conditions are common in HIV-infected and HIV-uninfected men who have sex with men (MSM). It is not well documented which anal HPV vaccine types are most prevalent in Southeast Asia. Methods: A convenience sample of 400 anal swabs were obtained from 200 HIV-infected and 200 HIV-uninfected sexually active Bangkok MSM Cohort Study participants. After swab collection in PreservCyt (Cytyc Corp,Marlborough,MA), the media was stored at.80°C until processing. DNA was extracted, amplified by polymerase chain reaction, denatured, and then hybridized to probes for 37 HPV types and â-globin. Results: The mean participant age was 25.6 years (range, 18-55 years); the mean CD4 T-cell count was 410 cells/mm3 in the HIV-infected participants. Among all swab samples, 386 (192 HIV-positive and 194 HIVnegative) had adequate â-globin for HPV genotype testing. Anal HPV type was detected in 44.3% of participants whose samples underwent genotype testing. Both qHPVand nHPV types were more frequently detected in HIVinfected compared with HIV-uninfected (42.2% vs. 23.2% [P < 0.01], 50.0% vs. 24.2% [P < 0.01]), respectively). There were no significant relationships between social behaviors (alcohol use, drug use) or sexual behaviors (number of partners, condom usage, sexual positioning) and anal HPV prevalence. Conclusions: The prevalence of anal vaccine HPV types in Thai MSM was similar to that reported in MSM from Western populations and has a similar distribution by HIV status. Targeting youngMSMwith vaccination could offer protection against HPV vaccine types.
UR - http://www.scopus.com/inward/record.url?scp=84947869519&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84947869519&partnerID=8YFLogxK
U2 - 10.1097/OLQ.0000000000000372
DO - 10.1097/OLQ.0000000000000372
M3 - Article
C2 - 26562695
AN - SCOPUS:84947869519
SN - 0148-5717
VL - 42
SP - 671
EP - 676
JO - Sexually Transmitted Diseases
JF - Sexually Transmitted Diseases
IS - 12
ER -